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Cardioverter-Deﬁbrillator
When Less Is More*Anne B. Curtis, MD, Hiroko Beck, MDL ed by a tremendous effort by Mirowski et al.(1), the implantable cardioverter-deﬁbrillator(ICD) was ﬁrst successfully implanted in
humans 35 years ago via an epicardial approach at
the Johns Hopkins Hospital (Baltimore, Maryland).
Subsequently, the development of transvenous leads
and smaller generators as well as the results of clin-
ical trials led to an explosion in the use of ICDs for pri-
mary and secondary prevention of sudden cardiac
death. More than 1 million patients have undergone
implantation over the last 3 decades (2). How-
ever, despite the widespread adoption of ICDs, the
transvenous implantable cardioverter-deﬁbrillator
(T-ICD) has recognized limitations, including the dif-
ﬁculty of implanting leads in patients with vascular
access issues, the vulnerability of leads to structural
damage over time, which necessitates additional
leads and/or lead extraction (a particular concern in
younger patients), and the risk of systemic infection.SEE PAGE 1605In an attempt to address these issues, the subcu-
taneous implantable cardioverter-deﬁbrillator (S-ICD)
was introduced in 2010 (3). Following Food and Drug
Administration approval in 2012, the S-ICD has been
steadily gaining in popularity, because it allows im-
plantation of a system without the need for endocar-
dial leads. The study by Burke et al. (4), in this issue of
the Journal, provides a large-scale evaluation of the*Editorials published in the Journal of the American College of Cardiology
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follow-up of 2 years, by combining the 2 largest pro-
spective studies of the S-ICD, IDE (S-ICD System IDE
Clinical Investigation) and EFFORTLESS (Boston Sci-
entiﬁc Post Market S-ICD Registry) (5,6). By pooling
these studies, Burke et al. (4) evaluated a large data-
base with 882 patients who received S-ICDs who were
followed for 651  345 days (1,571.5 patient-years),
which allowed an analysis of a larger cohort over a
longer duration of time. The results of this analysis
lent further support for the use of the S-ICD in appro-
priate patients. The success of shock therapy after up
to 5 shocks for ventricular tachyarrhythmias was
98.2%, and the estimated 3-year inappropriate shock
rate was 13.1%. The estimated all-cause mortality was
4.7% at 3 years with a total of 26 deaths, which was
2.9% of patients who underwent implantation, with
only 1 known arrhythmic death (0.1%) due to Loefﬂer’s
syndrome. Device-related complications occurred in
11.1% of patients at 3 years, but there was no S-ICD–
related endocarditis or bacteremia.
The S-ICD is certainly an attractive system to avoid
endocardial complications in the long run. However,
the lack of endocardial leads has certain speciﬁc im-
plications. First, the system does not provide pacing,
except for up to 30 s of post-shock ventricular pacing.
For this reason, the study methods excluded patients
who had episodes of ventricular tachycardia (VT)
of <170 beats/min that could potentially be termi-
nated by anti-tachycardia pacing (ATP). Therefore,
the index arrhythmia for the secondary prevention
patients in this study was predominantly ventricular
ﬁbrillation (VF) or polymorphic ventricular tachy-
cardia (PVT). Although the efﬁcacy of the S-ICD for VT
at <170 beats/min was higher compared with PVT/VF
(ﬁrst and second shock conversion rates of 91.7% and
100% for monomorphic VT vs. 88.2% and 96.1% for
PVT/VF, respectively), the known high efﬁcacy of ATP
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1617for VT (7) indicates that transvenous systems that
allow for painless ATP are preferable in patients with
a history of monomorphic VT. The S-ICD would also
not be appropriate in the occasional patient whose
arrhythmia might be suppressed by overdrive pacing.
The second broad category of patients for whom
the S-ICD would not be appropriate includes patients
who require pacing for bradycardia, atrioventricular
block, or cardiac resynchronization therapy. Such
patients should receive a de novo system with the
appropriate number and types of transvenous leads.
For patients with pre-existing endocardial pace-
makers, it is possible to implant an S-ICD system as
well, although additional screening processes are
necessary to avoid unfavorable device interactions.
For patients with existing pacemakers who require an
ICD upgrade, the risk and beneﬁt of lead extraction
and endocardial lead implantation versus the use
of an S-ICD system need to be carefully evaluated.
Fortunately, by using the inclusion and/or exclusion
criteria in these 2 studies, the future need for system
revision to allow transvenous pacing was quite low
(0.4%). Future generations of the S-ICD system may
incorporate pacing features that accommodate these
pacing requirements by using Blue Tooth and leadless
pacing technology.
A major cause of morbidity in patients with ICDs is
inappropriate shocks. The rate of inappropriate
shocks in this study was 13.5%, which is similar to the
rate of 11.5% reported in a substudy of MADIT II
(Multicenter Automatic Deﬁbrillator Implantation
Trial II) (8). However, inappropriate shocks have been
reduced in more recent studies to <5% in T-ICD sys-
tems with the use of newer algorithms for program-
ming that incorporate longer detection times and/or
higher rate cutoffs (9). The S-ICD features 2 possible
tachyarrhythmia detection zones: 1) a “shock-only”
zone, in which detection and therapy are based on
rate only; and 2) an additional “conditional zone,” in
which a morphology analysis algorithm is applied in
addition to rate. Burke et al. (4) pointed out that the
relatively high inappropriate shock rate reported in
this study was driven by the early experience in the
IDE study. With the increased use of programming of
2 zones of therapy over time in these 2 studies (from
51% in the ﬁrst quartile of enrolled patients to 95% in
the last quartile), the rate of inappropriate shocks wasreduced from 20.5% to 11.7% at 3 years. Although this
rate was still higher than that achieved in MADIT-RIT
(Multicenter Automatic Deﬁbrillator Implantation
Trial-Reduce Inappropriate Therapy) (9), we do not
have information on the rate cutoffs and detection
times programmed in the S-ICD studies, which were
left up to the discretion of the investigators. It is
possible that attention to these programming vari-
ables could have led to a further reduction in inap-
propriate shocks.
Although there was no bacteremia or endocarditis,
infection was a leading complication of S-ICD im-
plantation, with 1.7% of patients requiring extraction
due to infection. Compared with an earlier study (10),
in which there was a 5% risk of infection, this is a
signiﬁcant improvement. Better training in operative
preparation and technique, as well as aggressive
management of skin infection, appear to have low-
ered the risk of infection that could necessitate device
removal.
ICDs are meant to save lives, ideally with a
low rate of complications, including inappropriate
shocks. We want any patient to need an ICD rarely,
but when it is needed, we want it to work quickly
and effectively. We have learned that programming
to minimize shocks is just as effective as previous
approaches to programming, while lessening the
chances that a patient will receive unnecessary
shocks. We now know that removing the trans-
venous lead from the ICD system can be done safely
and effectively, and yields a potentially life-saving,
but less invasive, system that is appropriate for
many patients. Overall, ICD systems have become
simpler with respect to implantation techniques and
location, while remaining technologically sophisti-
cated. As the poet Robert Browning once wrote
(Andrea del Sarto, 1855):
Yet do much less, so much less, Someone says,
(I know his name, no matter) - so much less!
Well, less is more, Lucrezia.
—Robert Browning (11)
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